Skip to main content

Advertisement

SpringerLink
Log in

Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma

  • Letter to the Editor
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Vogelzang NJ, Porta C, Mutti L (2005) New agents in the management of malignant mesothelioma. Semin Oncol 32:336–350

    Article  PubMed  CAS  Google Scholar 

  2. Butnor KJ, Burchette JL, Sporn TA, Hammar SP, Roggli VL (2004) The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using single-source antibody with a review of the literature Arch Pathol Lab Med 128:538–543

    PubMed  Google Scholar 

  3. Catalano A, Rodilossi S, Rippo MR, Caprari P, Procopio A (2004) Induction of stem cell factor/C-kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells J Biol Chem 279:46706–46714

    Article  PubMed  CAS  Google Scholar 

  4. Villano JL, Husain AN, Stadler WM, Hanson LL, Vogelzang NJ, Kindler HL (2004) A phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM). Abs Am Assoc Clin Oncol 23:663 (abs. 7200)

    Google Scholar 

  5. Mathy A, Baas P, Dalesio O, van Zandwijk N (2005) Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial Lung Cancer 50:83–86

    Article  PubMed  Google Scholar 

  6. Cacciotti P, Barbone D, Porta C, Mutti L, Gaudino G (2004) STI571 and gemcitabine combined cell treatment as a novel approach to malignant mesothelioma therapy. Abs. VII meeting of the International Mesothelioma Interest Group (IMIG), p 99

Download references

Author information

Authors and Affiliations

  1. Medical Oncology, I.R.C.C.S. San Matteo University Hospital, Piazzale C. Golgi, 27100, Pavia, Italy

    Camillo Porta

  2. Local Health Authority 11, Piedmont, Italy

    Luciano Mutti

  3. Pneumology, Civic Hospital, Brescia, Italy

    Gianfranco Tassi

Authors
  1. Camillo Porta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luciano Mutti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gianfranco Tassi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Camillo Porta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Porta, C., Mutti, L. & Tassi, G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 59, 149–150 (2007). https://doi.org/10.1007/s00280-006-0243-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-006-0243-4

Keywords

Search

Navigation